STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START) (START)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01585298
Recruitment Status : Completed
First Posted : April 25, 2012
Last Update Posted : March 1, 2017
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
Study to evaluate bradycardiac events during first dose observation of fingolimod in MS patients

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Drug: FTY720 Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6996 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 1-week, Open-label, Multi-center Study to Explore Conduction Abnormalities During First Dose Administration of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Actual Study Start Date : June 29, 2012
Actual Primary Completion Date : December 12, 2016
Actual Study Completion Date : December 12, 2016

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Fingolimod Drug: FTY720

Primary Outcome Measures :
  1. Number of patients with bradyarrhythmic events [ Time Frame: baseline ]
    number of patients with bradyarrhythmia (2nd or 3rd AV block or heart rate below 40 beats per minute) in ECG during first dose observation

Secondary Outcome Measures :
  1. Number of patients with other conduction abnormalities in ECG [ Time Frame: baseline ]
    number of patients with conduction abnormalities such as QT prolongation, first degree AV block during treatment initiation

  2. Number of patients with cardiac adverse events [ Time Frame: 7 days ]
    occurrence of subsequent cardiac AEs and serious cardiac AEs during study

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with relapsing remitting MS with high disease activity despite treatment with a disease modifying therapy (> 1 relapse in the previous year, > 9 hyperintense T2 lesions or > 1 Gd-enhancing lesion or "non-responding" which could be defined as unchanged or increased relapse rate or ongoing severe relapses compared to previous year) or patients with rapidly evolving severe RRMS (e.g. > 2 relapses with disease progression in one year and > 1 Gd-enhancing lesion or with a significant increase in T2 lesions compared to a recent MRI).

Exclusion Criteria:

  • immunocompromised patients
  • active infections
  • pregnant or nursing women, women of childbearing potential unless using 2 reliable forms of contraception

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01585298

  Show 259 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Novartis Pharmaceuticals Identifier: NCT01585298     History of Changes
Other Study ID Numbers: CFTY720DDE17
First Posted: April 25, 2012    Key Record Dates
Last Update Posted: March 1, 2017
Last Verified: February 2017

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Multiple Sclerosis
conduction abnormalities
first dose observation

Additional relevant MeSH terms:
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Fingolimod Hydrochloride
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs